AMIHOT II Pivotal Trial
The AMIHOT II trial, sponsored by TherOx, was a randomized, international multicenter trial to evaluate the safety and effectiveness of SSO2 Therapy in the treatment of anterior wall AMI treated with PCI and stenting within 6 hours of reported symptom onset. TherOx announced the completion of this FDA-approved trial in October, 2007.
Results from the AMIHOT I and AMIHOT II trials showed a median 26% decrease in infarct size in anterior MI patients treated within 6 hours of symptom onset who received SSO2 Therapy following PCI with stenting, vs. a Control group which received PCI with stenting alone.* 30-day MACE comparison (Major Adverse Cardiac Events, including death, reinfarction, target vessel revascularization, and stroke) demonstrated non-inferiority compared to PCI with stenting alone.**
Get additional information about the AMIHOT II trial (PDF).
* Bayesian posterior probability of superiority = 96.9%. Results based on a Bayesian statistical analysis of the AMIHOT I and AMIHOT II clinical studies.
** Bayesian posterior probability of non-inferiority = 99.5% that the SSO2 Therapy group MACE rate is within 6% of the Control group MACE rate.
DISCLAIMER
Europe: The TherOx® DownStream® System, the TherOx® DownStream® Cartridge, and the TherOx® AO Catheter bear the CE Mark and are available for sale in Europe.
United States: In the United States, the TherOx® DownStream® System, the MI-Cath® Infusion Catheter, and the DownStream® AO Cartridge, are investigational devices. They are limited by United States law to investigational use. They are not for sale or distribution in the United States.
